Hvis en patient får svære hudreaktioner (≥ grad 3, US National Cancer Institute - Common Toxicity Criteria, NCI- CTC), skal behandlingen med cetuximab afbrydes.
If a patient experiences a severe skin reaction (≥ grade 3; US National Cancer Institute - Common Toxicity Criteria, NCI-CTC), cetuximab therapy must be interrupted.